These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Sodium-glucose cotransporter 2 inhibitors and inflammation in chronic kidney disease: Possible molecular pathways. Yaribeygi H; Butler AE; Atkin SL; Katsiki N; Sahebkar A J Cell Physiol; 2018 Jan; 234(1):223-230. PubMed ID: 30076706 [TBL] [Abstract][Full Text] [Related]
8. Effects of sodium-glucose cotransporter-2 inhibitors and aldosterone antagonists, in addition to renin-angiotensin system antagonists, on major adverse kidney outcomes in patients with type 2 diabetes and chronic kidney disease: A systematic review and network meta-analysis. Yang S; Zhao L; Mi Y; He W Diabetes Obes Metab; 2022 Nov; 24(11):2159-2168. PubMed ID: 35712807 [TBL] [Abstract][Full Text] [Related]
9. Cardiovascular and Renal Benefits of SGLT2 Inhibitors: A Narrative Review. Rabizadeh S; Nakhjavani M; Esteghamati A Int J Endocrinol Metab; 2019 Apr; 17(2):e84353. PubMed ID: 31372172 [TBL] [Abstract][Full Text] [Related]
10. SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation. Tuttle KR; Brosius FC; Cavender MA; Fioretto P; Fowler KJ; Heerspink HJL; Manley T; McGuire DK; Molitch ME; Mottl AK; Perreault L; Rosas SE; Rossing P; Sola L; Vallon V; Wanner C; Perkovic V Am J Kidney Dis; 2021 Jan; 77(1):94-109. PubMed ID: 33121838 [TBL] [Abstract][Full Text] [Related]
11. Sodium-glucose cotransporter-2 inhibition for heart failure with preserved ejection fraction and chronic kidney disease with or without type 2 diabetes mellitus: a narrative review. Mentz RJ; Brunton SA; Rangaswami J Cardiovasc Diabetol; 2023 Nov; 22(1):316. PubMed ID: 37974185 [TBL] [Abstract][Full Text] [Related]
12. An evaluation of empagliflozin and it's applicability to hypertension as a therapeutic option. Herat LY; Matthews VB; Magno AL; Kiuchi MG; Carnagarin R; Schlaich MP Expert Opin Pharmacother; 2020 Jul; 21(10):1157-1166. PubMed ID: 32301361 [TBL] [Abstract][Full Text] [Related]
13. Sodium/glucose cotransporter 2 inhibitors in chronic kidney disease and heart failure: ready for prime time in patients without diabetes. Vlasschaert C; Sidhu B; Silver SA Curr Opin Nephrol Hypertens; 2021 May; 30(3):361-368. PubMed ID: 33767064 [TBL] [Abstract][Full Text] [Related]
14. Anti-Inflammation and Anti-Oxidation: The Key to Unlocking the Cardiovascular Potential of SGLT2 Inhibitors and GLP1 Receptor Agonists. Myasoedova VA; Bozzi M; Valerio V; Moschetta D; Massaiu I; Rusconi V; Di Napoli D; Ciccarelli M; Parisi V; Agostoni P; Genovese S; Poggio P Antioxidants (Basel); 2023 Dec; 13(1):. PubMed ID: 38275636 [TBL] [Abstract][Full Text] [Related]
15. Significant reduction in chronic kidney disease progression with sodium-glucose cotransporter-2 inhibitors compared to dipeptidyl peptidase-4 inhibitors in adults with type 2 diabetes in a UK clinical setting: An observational outcomes study based on international guidelines for kidney disease. Idris I; Zhang R; Mamza JB; Ford M; Morris T; Banerjee A; Khunti K Diabetes Obes Metab; 2022 Nov; 24(11):2138-2147. PubMed ID: 35676798 [TBL] [Abstract][Full Text] [Related]
16. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes-cardiovascular and renal benefits in patients with chronic kidney disease. Milder TY; Stocker SL; Samocha-Bonet D; Day RO; Greenfield JR Eur J Clin Pharmacol; 2019 Nov; 75(11):1481-1490. PubMed ID: 31377891 [TBL] [Abstract][Full Text] [Related]
17. Fluid homeostasis induced by sodium-glucose cotransporter 2 inhibitors: novel insight for better cardio-renal outcomes in chronic kidney disease. Masuda T; Nagata D Hypertens Res; 2023 May; 46(5):1195-1201. PubMed ID: 36849579 [TBL] [Abstract][Full Text] [Related]
18. [IMPROVEMENT OF RENAL OUTCOMES WITH SODIUM-GLUCOSE COTRANSPORTER-2 (SGLT2) INHIBITORS]. Schechter M; Mosenzon O Harefuah; 2021 Oct; 160(10):671-678. PubMed ID: 34689438 [TBL] [Abstract][Full Text] [Related]
19. Targeting inflammatory signaling pathways with SGLT2 inhibitors: Insights into cardiovascular health and cardiac cell improvement. Alsereidi FR; Khashim Z; Marzook H; Gupta A; Al-Rawi AM; Ramadan MM; Saleh MA Curr Probl Cardiol; 2024 May; 49(5):102524. PubMed ID: 38492622 [TBL] [Abstract][Full Text] [Related]
20. Renal and Cardiac Implications of Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors: The State of the Science. Cruz JE; Ahuja T; Bridgeman MB Ann Pharmacother; 2018 Dec; 52(12):1238-1249. PubMed ID: 29911393 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]